Health-related quality of life (HRQoL) in newly diagnosed patients (pts) with chronic phase chronic myelogenous leukemia (CP CML) treated with bosutinib (BOS) or imatinib (IM)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 15_suppl; p. 6612
Main Authors Lipton, J. H., Trask, P. C., Cella, D., Duvillie, L., Powell, C., Ramanan, M. V., Maslyak, Z., Kim, D.
Format Journal Article
LanguageEnglish
Published 20.05.2011
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2011.29.15_suppl.6612